Testing repurposed HIV-like drugs for early Alzheimer’s symptoms
Part of Brain & nervous system, Mental health clinical trials.
This Phase 1 study tests whether an existing type of anti-viral medicine (nucleoside reverse transcriptase inhibitors) can help people with early Alzheimer’s disease. It also focuses on safety and proper dosing while measuring brain-related changes and memory-related symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 50 and 85 years old
- Have mild memory impairment or mild dementia due to Alzheimer’s, confirmed by specific clinical tests
- Have thinking test scores in the allowed range (MMSE 15 to 30) and a mild-to-moderate rating of dementia (CDR 0.5 to 2)
- Have a specific spinal-fluid (CSF) Alzheimer’s lab result showing the right pTau/Aβ42 pattern
- Be able to do study tests in the study language, and have a study partner who can attend visits and help with assessments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
This study enrolls people with no memory impairment, mild memory problems, or mild Alzheimer’s dementia to test how brain scans and cognitive tests relate to Alzheimer’s disease. It may help by contributing to better early diagnosis and by letting you see whether you fit into the study’s imaging and blood-test pathway.
This study tests an investigational drug, ARO-MAPT-SC, which targets a protein involved in Alzheimer's disease. It is for people with early Alzheimer's to see if the drug is safe and can slow the disease.
This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.
This Phase 1 trial tests how safe and tolerable ALN-APP is in people with early Alzheimer’s-related mild memory impairment or mild dementia. It may help researchers find a treatment path for early Alzheimer’s, while closely monitoring side effects and basic health markers.
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
Hear when a new Alzheimer Disease, Early Onset trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.